PACS Group delivered one of the more striking single-week moves in the healthcare space, surging 26% after a Q1 earnings beat that forced both bulls and remaining sceptics to reprice their positions.
The catalyst arrived Monday evening, May 11. Q1 EPS came in at $0.50, well clear of the $0.42 consensus. Revenue of $1.42 billion beat the $1.363 billion estimate. Management simultaneously affirmed full-year 2026 revenue guidance of $5.65 billion to $5.75 billion — in line with Street forecasts at the midpoint. The company also announced a $250 million share repurchase authorization, effective May 7. Taken together, the print checked every box the Street needed to lift the stock back toward its pre-regulatory-concern levels, and the shares ended Tuesday's session at $41.01.
Positioning before the print told a cautious story. Short interest had been building steadily — up roughly 13% over the week heading into earnings, reaching 3.07% of the free float. That rebuild had been underway through late April and early May, even as the stock drifted sideways. The borrow market, however, remained far from strained: availability is still loose, cost to borrow barely moved at 0.47%, and the lending pool shows no meaningful tightness. Short interest, while trending higher, sat well short of squeeze territory. Those shorts now face mark-to-market pain following the 22% next-day move — the sharpest post-earnings reaction in the available history, with the prior comparable (March 2026) generating a much more muted 4% move. The ORTEX short score has ticked up to 56.2, its highest reading of the past two weeks, reflecting the building — and now battered — short position.
Options positioning had edged slightly more cautious ahead of the release. The put/call ratio climbed to 0.12, modestly above its 20-day average and roughly 1.3 standard deviations elevated. By the PCR's own 52-week range — the high is 1.55 and the floor is 0.09 — the reading was far from extreme, suggesting investors were hedging at the margins rather than making a directional call.
The analyst response was swift. Oppenheimer's Michael Wiederhorn raised his target from $42 to $48 on May 13, maintaining his Outperform rating. That follows a pattern of incremental target lifts across coverage: UBS moved its Buy target from $42 to $44 in March, while RBC Capital pushed to $52 in February. The mean price target now sits at $47.83, leaving roughly 17% upside to consensus from current levels. The PE has repriced to 17.5x on the earnings beat, and EV/EBITDA now runs at 16.2x — both moving sharply through the week. EPS momentum scores rank in the 73rd percentile over both 30- and 90-day windows, and the earnings surprise score sits at the 78th percentile, consistent with a track record of beating estimates. The dividend score ranks at an exceptional 92nd percentile.
The insider picture deserves a note. On April 15, multiple executives sold shares at $33.14 — the President/COO offloaded nearly $6.5 million worth, the Chief Legal Officer sold $2.2 million, and the Chief Accounting Officer sold $818,000. These were the largest insider transactions in recent months, and all occurred roughly four weeks before a Q1 print that drove the stock 24% above those sale prices. Scheduled sales (often tied to 10b5-1 plans) can explain the timing, but the gap between the April exit price and this week's close is notable context.
PACS also announced a CFO change in late April, with Carey P. Hendrickson replacing founder and Executive Vice Chairman Mark Hancock in the role. Hancock remains a top-two shareholder with over 34% of shares. That leadership transition — combined with the upcoming Q2 print scheduled for May 20 — is the next event that will determine whether this week's re-rating holds or prompts another round of repositioning.
See the live data behind this article on ORTEX.
Open PACS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
